{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:17Z","timestamp":1740144077081,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40261-020-00967-7","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T12:03:01Z","timestamp":1599220981000},"page":"1053-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety of Direct Oral Anticoagulants in the Secondary Stroke Prevention of Elderly Patients: Ljubljana Registry of Secondary Stroke Prevention"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-160X","authenticated-orcid":false,"given":"Senta","family":"Frol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana Podnar","family":"Sernec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam Koro\u0161ec","family":"Hudnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0161o","family":"\u0160abovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janja Pretnar","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"issue":"12","key":"967_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"967_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med."},{"issue":"11","key":"967_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"key":"967_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"967_CR5","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.","journal-title":"BMJ"},{"issue":"1","key":"967_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/joim.12683","volume":"283","author":"L Staerk","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45\u201355.","journal-title":"J Intern Med"},{"key":"967_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ahj.2017.08.018","volume":"198","author":"MV Huisman","year":"2018","unstructured":"Huisman MV, Rothman KJ, Paquette M, et al. Two-year follow up of patients treated with dabigatran for stroke prevention in atrial fibrillation: global registry on long-term antithrobotic treatement in patients with atrial fibrillation (GLORIA-AF) registry. Am Heart J. 2018;198:55\u201363.","journal-title":"Am Heart J"},{"issue":"38","key":"967_CR8","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","volume":"37","author":"JP Bassand","year":"2016","unstructured":"Bassand JP, Acetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882\u20139.","journal-title":"Eur Heart J"},{"key":"967_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest"},{"key":"967_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"967_CR11","unstructured":"Bagar S, Sluga D\u010c, Hladnik M, Jandl M, Majcan Kopilovi\u0107 I, Kravanja M, et al. Zdravstveno stanje prebivalstva: umrljivost. In: Zdravstveni statisti\u010dni letopis Slovenije 2017. National institute of public health (NIJZ). 2018. Available at: http:\/\/www.nijz.si\/sites\/www.nijz.si\/files\/uploaded\/publikacije\/letopisi\/2017\/2.1_umrljivostza_2017.pdf. Accessed 7 Apr 2020."},{"key":"967_CR12","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864\u201370.","journal-title":"JAMA"},{"key":"967_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40266-019-00710-8","volume":"36","author":"A Bruneau","year":"2019","unstructured":"Bruneau A, Schwab C, Anfosso M, Fernandez C, Hindlet P. Burden of inappropriate prescription of direct oral anticoagulants at hospital admission and discharge in the elderly: a prospective observational multicenter study. Drugs Aging. 2019;36:1047\u201355.","journal-title":"Drugs Aging"},{"issue":"12","key":"967_CR14","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"G Lip","year":"2018","unstructured":"Lip G, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49(12):2933\u201344.","journal-title":"Stroke"},{"issue":"2","key":"967_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","volume":"106","author":"A Banerjee","year":"2020","unstructured":"Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119\u201326.","journal-title":"Heart"},{"issue":"2","key":"967_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/ijerph16020196","volume":"16","author":"E Cheiloudaki","year":"2019","unstructured":"Cheiloudaki E, Alexopoulos EC. Adherence to treatment in stroke patients. Int J Environ Res Public Health. 2019;16(2):196.","journal-title":"Int J Environ Res Public Health."},{"issue":"2","key":"967_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2396987318812644","volume":"4","author":"K Haas","year":"2019","unstructured":"Haas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R. Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J. 2019;4(2):181\u20138.","journal-title":"Eur Stroke J."},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhame P, Potpara T, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagnonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330\u201393.","journal-title":"Eur Heart J"},{"issue":"7","key":"967_CR19","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45(7):2160\u2013236.","journal-title":"Stroke"},{"key":"967_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson M, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326\u201335.","journal-title":"N Engl J Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00967-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T01:44:18Z","timestamp":1630719858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00967-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00967-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"4 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SF and JPO contributed to study design, data collection, data interpretation, and manuscript drafts. MS contributed to study design, data interpretation, and manuscript drafts. LPS and LKH contributed to data collection, data interpretation, and manuscript drafts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"In the past 2\u00a0years, J.P.O., M.S. and S.F. have received honoraria for oral presentations from Bayer, Boehringer Ingelheim and Pfizer Inc. L.P.S. and L.K.H. have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}]}}